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DOI 10.1016/j.chembiol.2009.05.003The spotlight has again focused on the
human embryonic stem cell (hESC)
discussion in the United States. But this
time, the discussion goes beyond talk
about funding issues. In the 8 years since
a federal ban was placed on federal
support of hESC research, new stem
cell technologies have been developed
that some believe may hold near equal
promise as hESC. Others disagree, but
shifting policies under the new US
administration place hESC research—
and planned commercial applications—
once again front and center.
In August 2001, US President George
W. Bush issued an order barring the useGoing beyond this template, re-
searchers throughout the world, including
those in the US, continued on the quest
for stem cell advances. As a result, several
new types of stem cell technologies were
developed, the most notable of which is
the inducible pluripotent stem cell, or iPS
cell, first described in 2006 by Shinya
Yamanaka of Kyoto University, using
adult mouse skin cells (Takahashi and
Yamanaka, 2006) Embryonic tissue is not
involved in their generation. Instead, the
classical way of making them involves re-
programming of an adult cell through intro-
duction of four genes, Oct4, Sox2, c-Myc
and Klf4, found in pluripotent stem cells.In January 2009, the FDA granted Geron the first-ever US
approval to initiate a human clinical trial with human embryonic
stem cells.of federal money to support stem cell
research using donated embryos from
in vitro fertilization (IVF) clinics that
resulted in the destruction of the embryos.
The current US President, Barack Obama,
seemingly reversed this policy in March
2009 with his own executive order to
again make the National Institute of
Health (NIH) funds available for hESC
research.
In the 8 years from the start of the
federal funding ban, however, basic
stem cell researchers have gone quietly
about their business devising new tech-
nologies to advance the field.
2001 through 2009: Time Not
Wasted
The classical hESC is isolated from
a donated blastocyst from an IVF clinic.
The inner cell mass region of a blastocyst
contains a small group of 50–100 pluripo-
tent cells. These cells, human embryonic
stem cells, can eventually give rise to all
the cells, somatic tissues, and organs in
the body.There are a variety of ways to do this,
some using viruses, DNA constructs, or
protein transduction. Regardless of how it
is achieved thus far, the reprogrammed
cell shows what appear to be the same
properties of an ESC.
‘‘Yamanaka’s 2006 cells met the defini-
tion of pluripotency,’’ explains M. William
Lensch, Ph.D., Affiliate Faculty, the Har-
vard Stem Cell Institute. ‘‘But if you tried
to make mice out of them, they would
only develop so far. He never got live-
born pups.’’ These cells did not advance
far enough to make germline (oocyte or
sperm cell) contributions.
But 1 year later, in the summer of 2007,
Yamanaka and others used the exact
same reprogramming process to isolate
a different population from that reprog-
rammed pool (Okita et al., 2007). Those
cells were able to make live-born pups
and they also went germline. ‘‘That tells
us that in this reprogramming process
there are probably different functional
subpopulations and you have to try and
find the best ones,’’ says Lensch.Chemistry & Biology 16, May 29, 200But the world of iPS research is
not without its own concerns. Some re-
searchers are concerned that the tools
needed to reprogram the adult cells,
such as viruses and introduced novel
genes, may trigger oncogene expression
or cause other as yet unknown harm.
Using natural hESCs by definition avoids
these concerns, one of the many reasons
some companies remain dedicated to
using them for clinical applications.
Geron Leading the Field
Perhaps no other company involved in
hESC work has remained as dedicated to
its mission as Geron Corporation in Menlo
Park, CA. Over the past decade, Geron has
spent $175 million on its hESC platform, all
of it from private funds. The company is
pursuing hESC cell replacement therapy,
focused initially on patients with spinal
cord injury. In January 2009, the U.S.
Food and Drug Administration (FDA)
granted Geron the first-ever US approval
to initiate a human clinical trial with hESCs.
‘‘All of our intended treatments are single
injections,’’ says Thomas Okarma, Geron
CEO. ‘‘That is the power of this therapy.
We show in animal models that these cells
live indefinitely and the repair is perma-
nent.’’ The trial, which Geron hopes to
initiate beginning in the summer of 2009,
involves eight centers and is aimed at
establishing safety. ‘‘It is a relatively low
dose of cells and that is done for safety
purposes,’’ says Okarma. ‘‘We are inject-
ing them into patients with complete
thoracic injuries. These cells are alive,
they migrate through the lesion, and they
divide. Theymultiply after theyare injected,
so there is a finite possibility that even at
this low dose these patients might have
a durable partial response and that is how
we compute the risk benefit ratio for these
patients.’’ Okarma stresses he does not
expect to see improvement in the patients
in this study, but it may be a possibility.
‘‘The other forms of pluripotent stem
cells, which are really only iPS in terms9 ª2009 Elsevier Ltd All rights reserved 471
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really nowhere near where embryonics
are,’’ offers Okarma. ‘‘We’ve been work-
ing with these cells for 10 years and they
are the gold standard for naturally
occurring, normal human pluripotent
stem cells. Everything else is a proxy.’’
His belief is that iPS cells will have utility
when derived from patients with genetic
diseases from which certain differentiated
cells could be made and then used for
screening, for drugs, or for unraveling
abnormal pathways. ‘‘These iPS cells are
definitely mutant cells,’’ says Okarma.
‘‘They are abnormal. Regardless of how
they are made, even if eventually chemi-
cals can be used to reprogram them,
they are by definition absolutely different
from one another and ESCs in their gene
expression pattern. And I can say that
having gone through the labors of getting
hESCs through the FDA, that the gene-
modified stem cell as the beginning of
a process to manufacture a differentiated
cell therapy would never fly with the FDA.’’
A Party to Both Camps
Other companies are taking a more
diverse approach to stem cell commer-
cialization. Novocell, Inc., of San Diego,
CA, for example, is developing hESCs
from embryonic tissue and has also
partnered with iPS developer Shiya
Yamanaka to explore the promise of iPS
technology for making pancreatic islet
cells. ‘‘At this point, hESCs are the gold
standard for making a cell-replacement
therapy for most cell replacement appli-
cations, in our opinion,’’ says E. Edward
Baetge, Ph.D., Chief Scientific Officer at
Novocell. ‘‘But we are very interested in
looking at cells such as iPS cells that
have the same properties as hESCs. I
don’t think they are exactly identical to
hESC at this point, but they are the closest
that anyone has ever been able to make.
The future of ESC biology may reside
with iPS cells, so we are very interested
to understand how well these types of
cells perform in comparison to hESC.’’472 Chemistry & Biology 16, May 29, 2009 ªThe company is targeting pancreatic
islet cells for cell replacement therapy in
diabetes.
‘‘When you make an iPS cell, what you
are doing is reprogramming something
that is an adult cell that doesn’t have any
embryonic properties whatsoever, and
you’re counting on those four genes to
actually reprogram that skin cell all the
way back to the ESC state you can get
from a blastocyst,’’ says Baetge. ‘‘Is the
iPS cell a perfect replica of a hESC? If
you ask most people who work in this
field, the answer would be no.’’
An Academic’s View
‘‘We have everything on the table,’’ says
Lensch, who is also a senior scientist in
the laboratory of well-known stem cell
researcher George Daley at Boston’s
Children’s Hospital. ‘‘We have derived
our own ESC lines. And we are also one
of the labs which has done a lot of work
on inducible pluripotent cells, cord blood
work, lots of different complementary
approaches. The fact that we do all these
things side by side in the lab gives us
a unique perspective.’’
Stem cell researchers use the mouse
ESC system to dig deeper into stem cell
machinery, performing assays and tech-
niques not ethically possible with human
embryonic stem cells. ‘‘What the field is
trying to do as a whole, especially by
being able to take advantage of things in
mouse systems, is to take the cells we
know function the best, like mouse
ESCs, and ask why some of these reprog-
rammed cells are better mechanistically
than others,’’ says Lensch. ‘‘Hopefully,
we then would come to understand the
intracellular machinery of what makes
truly terrific pluripotent cells and see if
we can use that as a surrogate signature
for any reprogrammed cell that comes
forward.’’ But even in the mouse system
where researchers have done a variety
of amazing things, ‘‘we still have not
been able to reprogram a cell to be the
functional equivalent of your average2009 Elsevier Ltd All rights reservedESC,’’ he says. ‘‘How are we going to be
able to find that cell? Because we have
a cell that is functional in every way—the
embryonic stem cell—and we can use it
in comparisons to all these other types.
It is definitely the gold standard.’’
Researchers engaged in basic ESC
work in the US understandably welcome
President Obama’s executive order.
Currently, approximately 22 hESC lines
are eligible for NIH funding. ‘‘But after
6 dedicated hours searching online, I
counted nearly 800 cell lines developed
by researchers throughout the world,’’
says Lensch. ‘‘That is a huge resource
that as of today we can’t get NIH funding
to study.’’ And he admits that an influx of
NIH funding would alleviate some of the
separate tracking required in his labora-
tory between ‘‘NP’’ (for non-Presidential)
research and federally funded projects.
But at the end of the day, Lensch
believes that most people working in the
field are not focused on the mechanism
of reprogramming. ‘‘What they want are
large quantities of pluripotent cells
because they want to study the develop-
ment of a specific type of tissue.’’
The scientific discussion rolls on just as
the details of the Obama executive order
are negotiated. To date, no federal funds
have been released for the study of
human embryonic stem cell research
under the Obama plan. Final recommen-
dations and guidelines from the NIH are
pending once the public commentary
period closes in late May 2009.
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